1 Table of Contents 2
1.1 List of Tables 9
1.2 List of Figures 17
2 Introduction 18
2.1 Colorectal Cancer Overview 18
3 Products under Development 19
3.1 Colorectal Cancer – Pipeline Products by Stage of Development 19
3.2 Colorectal Cancer – Pipeline Products by Territory 20
3.3 Colorectal Cancer – Pipeline Products by Regulatory Path 21
3.4 Colorectal Cancer – Pipeline Products by Estimated Approval Date 22
3.5 Colorectal Cancer – Ongoing Clinical Trials 23
4 Colorectal Cancer – Pipeline Products under Development by Companies 24
4.1 Colorectal Cancer Companies – Pipeline Products by Stage of Development 24
4.2 Colorectal Cancer – Pipeline Products by Stage of Development 29
5 Colorectal Cancer Companies and Product Overview 33
5.1 Abcodia Ltd Company Overview 33
5.1.1 Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview 33
5.2 Almac Diagnostic Services Ltd Company Overview 34
5.2.1 Almac Diagnostic Services Ltd Pipeline Products & Ongoing Clinical Trials Overview 34
5.3 Ambergen Inc Company Overview 35
5.3.1 Ambergen Inc Pipeline Products & Ongoing Clinical Trials Overview 35
5.4 Anixa Diagnostics Corporation Company Overview 36
5.4.1 Anixa Diagnostics Corporation Pipeline Products & Ongoing Clinical Trials Overview 36
5.5 Applied Proteomics Inc Company Overview 41
5.5.1 Applied Proteomics Inc Pipeline Products & Ongoing Clinical Trials Overview 41
5.6 Arizona State University Company Overview 42
5.6.1 Arizona State University Pipeline Products & Ongoing Clinical Trials Overview 42
5.7 Arrayit Corporation Company Overview 43
5.7.1 Arrayit Corporation Pipeline Products & Ongoing Clinical Trials Overview 43
5.8 ArtemixRx Company Overview 44
5.8.1 ArtemixRx Pipeline Products & Ongoing Clinical Trials Overview 44
5.9 Avant Diagnostics Inc Company Overview 45
5.9.1 Avant Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 45
5.10 Bio Mark Ltd Company Overview 46
5.10.1 Bio Mark Ltd Pipeline Products & Ongoing Clinical Trials Overview 46
5.11 Biocartis Group NV Company Overview 47
5.11.1 Biocartis Group NV Pipeline Products & Ongoing Clinical Trials Overview 47
5.12 Biodesix Inc Company Overview 49
5.12.1 Biodesix Inc Pipeline Products & Ongoing Clinical Trials Overview 49
5.13 BioMarCare Technologies Ltd Company Overview 50
5.13.1 BioMarCare Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 50
5.14 BioMark Diagnostics Inc Company Overview 51
5.14.1 BioMark Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 51
5.15 BioMarker Strategies LLC Company Overview 52
5.15.1 BioMarker Strategies LLC Pipeline Products & Ongoing Clinical Trials Overview 52
5.16 Biomoda Inc Company Overview 53
5.16.1 Biomoda Inc Pipeline Products & Ongoing Clinical Trials Overview 53
5.17 Bioprognos SL Company Overview 54
5.17.1 Bioprognos SL Pipeline Products & Ongoing Clinical Trials Overview 54
5.18 BioSystems International Company Overview 55
5.18.1 BioSystems International Pipeline Products & Ongoing Clinical Trials Overview 55
5.19 Biotron Ltd Company Overview 56
5.19.1 Biotron Ltd Pipeline Products & Ongoing Clinical Trials Overview 56
5.20 Calviri Inc Company Overview 57
5.20.1 Calviri Inc Pipeline Products & Ongoing Clinical Trials Overview 57
5.21 Castle Biosciences Inc Company Overview 58
5.21.1 Castle Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 58
5.22 Catholic University of Leuven Company Overview 59
5.22.1 Catholic University of Leuven Pipeline Products & Ongoing Clinical Trials Overview 59
5.23 Celcuity Inc Company Overview 60
5.23.1 Celcuity Inc Pipeline Products & Ongoing Clinical Trials Overview 60
5.24 CellMax Life Inc Company Overview 61
5.24.1 CellMax Life Inc Pipeline Products & Ongoing Clinical Trials Overview 61
5.25 Cellmid Ltd Company Overview 62
5.25.1 Cellmid Ltd Pipeline Products & Ongoing Clinical Trials Overview 62
5.26 Ceres Nanosciences Inc Company Overview 64
5.26.1 Ceres Nanosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 64
5.27 Cernostics Inc Company Overview 65
5.27.1 Cernostics Inc Pipeline Products & Ongoing Clinical Trials Overview 65
5.28 ChemImage Corp Company Overview 66
5.28.1 ChemImage Corp Pipeline Products & Ongoing Clinical Trials Overview 66
5.29 China Sky One Medical Inc Company Overview 67
5.29.1 China Sky One Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 67
5.30 Columbia University Company Overview 68
5.30.1 Columbia University Pipeline Products & Ongoing Clinical Trials Overview 68
5.31 CS-Keys, Inc. (Inactive) Company Overview 69
5.31.1 CS-Keys, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 69
5.32 Di.V.A.L Toscana srl Company Overview 70
5.32.1 Di.V.A.L Toscana srl Pipeline Products & Ongoing Clinical Trials Overview 70
5.33 DiagnoCure Inc. (Inactive) Company Overview 71
5.33.1 DiagnoCure Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 71
5.34 Diazyme Laboratories Inc Company Overview 73
5.34.1 Diazyme Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 73
5.35 DNAlytics SA Company Overview 74
5.35.1 DNAlytics SA Pipeline Products & Ongoing Clinical Trials Overview 74
5.36 Duke University Company Overview 75
5.36.1 Duke University Pipeline Products & Ongoing Clinical Trials Overview 75
5.37 EDP Biotech Corporation Company Overview 76
5.37.1 EDP Biotech Corporation Pipeline Products & Ongoing Clinical Trials Overview 76
5.38 EntreChem SL Company Overview 77
5.38.1 EntreChem SL Pipeline Products & Ongoing Clinical Trials Overview 77
5.39 Epigenomics AG Company Overview 78
5.39.1 Epigenomics AG Pipeline Products & Ongoing Clinical Trials Overview 78
5.40 Eurobio Scientific SA Company Overview 79
5.40.1 Eurobio Scientific SA Pipeline Products & Ongoing Clinical Trials Overview 79
5.41 Eventus Diagnostics Inc (Inactive) Company Overview 80
5.41.1 Eventus Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 80
5.42 Exact Sciences Corp Company Overview 81
5.42.1 Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 81
5.43 Exiqon AS Company Overview 82
5.43.1 Exiqon AS Pipeline Products & Ongoing Clinical Trials Overview 82
5.44 Exosomics Siena SpA Company Overview 83
5.44.1 Exosomics Siena SpA Pipeline Products & Ongoing Clinical Trials Overview 83
5.45 Fina Biotech SL Company Overview 84
5.45.1 Fina Biotech SL Pipeline Products & Ongoing Clinical Trials Overview 84
5.46 Fox Chase Cancer Center Company Overview 85
5.46.1 Fox Chase Cancer Center Pipeline Products & Ongoing Clinical Trials Overview 85
5.47 GenExosome Technologies Inc Company Overview 87
5.47.1 GenExosome Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 87
5.48 GenomicTree Co Ltd Company Overview 88
5.48.1 GenomicTree Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 88
5.49 German Cancer Research Center Company Overview 92
5.49.1 German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 92
5.50 Ghent University Company Overview 94
5.50.1 Ghent University Pipeline Products & Ongoing Clinical Trials Overview 94
5.51 GlycoZym USA Inc Company Overview 95
5.51.1 GlycoZym USA Inc Pipeline Products & Ongoing Clinical Trials Overview 95
5.52 Health Discovery Corp Company Overview 96
5.52.1 Health Discovery Corp Pipeline Products & Ongoing Clinical Trials Overview 96
5.53 Hitachi Chemical Diagnostics Inc Company Overview 97
5.53.1 Hitachi Chemical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 97
5.54 Human Metabolome Technologies Inc Company Overview 98
5.54.1 Human Metabolome Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 98
5.55 Ikonisys Inc Company Overview 99
5.55.1 Ikonisys Inc Pipeline Products & Ongoing Clinical Trials Overview 99
5.56 Institute of Molecular and Translational Medicine Company Overview 100
5.56.1 Institute of Molecular and Translational Medicine Pipeline Products & Ongoing Clinical Trials Overview 100
5.57 InterGenetics Inc Company Overview 101
5.57.1 InterGenetics Inc Pipeline Products & Ongoing Clinical Trials Overview 101
5.58 Johns Hopkins University Company Overview 102
5.58.1 Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 102
5.59 King Abdullah University of Science and Technology Company Overview 104
5.59.1 King Abdullah University of Science and Technology Pipeline Products & Ongoing Clinical Trials Overview 104
5.60 Kyo Diagnostics KK Company Overview 105
5.60.1 Kyo Diagnostics KK Pipeline Products & Ongoing Clinical Trials Overview 105
5.61 Lab21 Ltd Company Overview 106
5.61.1 Lab21 Ltd Pipeline Products & Ongoing Clinical Trials Overview 106
5.62 Laboratorios Alpha San Ignacio Pharma S.L. Company Overview 107
5.62.1 Laboratorios Alpha San Ignacio Pharma S.L. Pipeline Products & Ongoing Clinical Trials Overview 107
5.63 Leitat Technological Center Company Overview 108
5.63.1 Leitat Technological Center Pipeline Products & Ongoing Clinical Trials Overview 108
5.64 MabCure Inc Company Overview 110
5.64.1 MabCure Inc Pipeline Products & Ongoing Clinical Trials Overview 110
5.65 Master Diagnostica Sociedad Limitada Company Overview 111
5.65.1 Master Diagnostica Sociedad Limitada Pipeline Products & Ongoing Clinical Trials Overview 111
5.66 Matrix-Bio Inc Company Overview 112
5.66.1 Matrix-Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 112
5.67 Max Delbruck Center for Molecular Medicine Company Overview 115
5.67.1 Max Delbruck Center for Molecular Medicine Pipeline Products & Ongoing Clinical Trials Overview 115
5.68 Mayo Clinic Company Overview 116
5.68.1 Mayo Clinic Pipeline Products & Ongoing Clinical Trials Overview 116
5.69 MDNA Life Sciences Inc Company Overview 117
5.69.1 MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 117
5.70 MDxHealth SA Company Overview 118
5.70.1 MDxHealth SA Pipeline Products & Ongoing Clinical Trials Overview 118
5.71 Merrimack Pharmaceuticals Inc Company Overview 120
5.71.1 Merrimack Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 120
5.72 Metabolon Inc Company Overview 121
5.72.1 Metabolon Inc Pipeline Products & Ongoing Clinical Trials Overview 121
5.73 MetaStat Inc Company Overview 122
5.73.1 MetaStat Inc Pipeline Products & Ongoing Clinical Trials Overview 122
5.74 Milagen Inc Company Overview 123
5.74.1 Milagen Inc Pipeline Products & Ongoing Clinical Trials Overview 123
5.75 Myriad Genetics Inc Company Overview 124
5.75.1 Myriad Genetics Inc Pipeline Products & Ongoing Clinical Trials Overview 124
5.76 Nanocytomics LLC Company Overview 125
5.76.1 Nanocytomics LLC Pipeline Products & Ongoing Clinical Trials Overview 125
5.77 Norda ASA Company Overview 126
5.77.1 Norda ASA Pipeline Products & Ongoing Clinical Trials Overview 126
5.78 Novel Bio-spectrum Technologies Inc (Inactive) Company Overview 127
5.78.1 Novel Bio-spectrum Technologies Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 127
5.79 Nuclea Biotechnologies Inc. (Inactive) Company Overview 128
5.79.1 Nuclea Biotechnologies Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 128
5.80 Oncimmune (USA) LLC Company Overview 129
5.80.1 Oncimmune (USA) LLC Pipeline Products & Ongoing Clinical Trials Overview 129
5.81 OncoCyte Corp Company Overview 130
5.81.1 OncoCyte Corp Pipeline Products & Ongoing Clinical Trials Overview 130
5.82 Onconome, Inc. (Inactive) Company Overview 131
5.82.1 Onconome, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 131
5.83 Origin Sciences Ltd Company Overview 132
5.83.1 Origin Sciences Ltd Pipeline Products & Ongoing Clinical Trials Overview 132
5.84 Orion Genomics LLC Company Overview 133
5.84.1 Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview 133
5.85 OTraces Inc Company Overview 134
5.85.1 OTraces Inc Pipeline Products & Ongoing Clinical Trials Overview 134
5.86 Oxford Cancer Biomarkers Ltd Company Overview 135
5.86.1 Oxford Cancer Biomarkers Ltd Pipeline Products & Ongoing Clinical Trials Overview 135
5.87 Oxford Gene Technology Ltd Company Overview 136
5.87.1 Oxford Gene Technology Ltd Pipeline Products & Ongoing Clinical Trials Overview 136
5.88 PleX Diagnostics Inc (Inactive) Company Overview 137
5.88.1 PleX Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 137
5.89 Precision Biologics Inc Company Overview 138
5.89.1 Precision Biologics Inc Pipeline Products & Ongoing Clinical Trials Overview 138
5.90 Prediction Sciences LLC (Inactive) Company Overview 139
5.90.1 Prediction Sciences LLC (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 139
5.91 PreMD Inc (Inactive) Company Overview 140
5.91.1 PreMD Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 140
5.92 Prescient Medicine LLC Company Overview 141
5.92.1 Prescient Medicine LLC Pipeline Products & Ongoing Clinical Trials Overview 141
5.93 Protagen AG Company Overview 142
5.93.1 Protagen AG Pipeline Products & Ongoing Clinical Trials Overview 142
5.94 Protein Alternatives SL Company Overview 143
5.94.1 Protein Alternatives SL Pipeline Products & Ongoing Clinical Trials Overview 143
5.95 Qiagen NV Company Overview 144
5.95.1 Qiagen NV Pipeline Products & Ongoing Clinical Trials Overview 144
5.96 Quest Diagnostics Inc Company Overview 145
5.96.1 Quest Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 145
5.97 Rabin Medical Center Company Overview 146
5.97.1 Rabin Medical Center Pipeline Products & Ongoing Clinical Trials Overview 146
5.98 Rhythm Biosciences Ltd Company Overview 147
5.98.1 Rhythm Biosciences Ltd Pipeline Products & Ongoing Clinical Trials Overview 147
5.99 RISE Life Science Corp Company Overview 150
5.99.1 RISE Life Science Corp Pipeline Products & Ongoing Clinical Trials Overview 150
5.100 Rosetta Genomics Ltd Company Overview 151
5.100.1 Rosetta Genomics Ltd Pipeline Products & Ongoing Clinical Trials Overview 151
5.101 Sanguine Diagnostics and Therapeutics Inc Company Overview 152
5.101.1 Sanguine Diagnostics and Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 152
5.102 Scienion AG Company Overview 153
5.102.1 Scienion AG Pipeline Products & Ongoing Clinical Trials Overview 153
5.103 Seegene Inc Company Overview 154
5.103.1 Seegene Inc Pipeline Products & Ongoing Clinical Trials Overview 154
5.104 Shuwen Biotech Co Ltd Company Overview 155
5.104.1 Shuwen Biotech Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 155
5.105 Sysmex Corp Company Overview 156
5.105.1 Sysmex Corp Pipeline Products & Ongoing Clinical Trials Overview 156
5.106 Tel Aviv University Company Overview 157
5.106.1 Tel Aviv University Pipeline Products & Ongoing Clinical Trials Overview 157
5.107 The Walter and Eliza Hall Institute of Medical Research Company Overview 158
5.107.1 The Walter and Eliza Hall Institute of Medical Research Pipeline Products & Ongoing Clinical Trials Overview 158
5.108 TheraDiag SA Company Overview 159
5.108.1 TheraDiag SA Pipeline Products & Ongoing Clinical Trials Overview 159
5.109 Treos Bio Inc Company Overview 161
5.109.1 Treos Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 161
5.110 Trinity College Dublin Company Overview 162
5.110.1 Trinity College Dublin Pipeline Products & Ongoing Clinical Trials Overview 162
5.111 Universal Diagnostics SL Company Overview 163
5.111.1 Universal Diagnostics SL Pipeline Products & Ongoing Clinical Trials Overview 163
5.112 University of Illinois at Chicago Company Overview 164
5.112.1 University of Illinois at Chicago Pipeline Products & Ongoing Clinical Trials Overview 164
5.113 University of Lyon Company Overview 165
5.113.1 University of Lyon Pipeline Products & Ongoing Clinical Trials Overview 165
5.114 University of Michigan Company Overview 166
5.114.1 University of Michigan Pipeline Products & Ongoing Clinical Trials Overview 166
5.115 University of Notre Dame Company Overview 167
5.115.1 University of Notre Dame Pipeline Products & Ongoing Clinical Trials Overview 167
5.116 University of Texas MD Anderson Cancer Center Company Overview 168
5.116.1 University of Texas MD Anderson Cancer Center Pipeline Products & Ongoing Clinical Trials Overview 168
5.117 University of Turku Company Overview 170
5.117.1 University of Turku Pipeline Products & Ongoing Clinical Trials Overview 170
5.118 University of Washington Company Overview 171
5.118.1 University of Washington Pipeline Products & Ongoing Clinical Trials Overview 171
5.119 University of Wisconsin Madison Company Overview 172
5.119.1 University of Wisconsin Madison Pipeline Products & Ongoing Clinical Trials Overview 172
5.120 University of Zurich Company Overview 173
5.120.1 University of Zurich Pipeline Products & Ongoing Clinical Trials Overview 173
5.121 US Biomarkers Inc Company Overview 174
5.121.1 US Biomarkers Inc Pipeline Products & Ongoing Clinical Trials Overview 174
5.122 vall d hebron institut de Recerca Company Overview 175
5.122.1 vall d hebron institut de Recerca Pipeline Products & Ongoing Clinical Trials Overview 175
5.123 Vanderbilt University Company Overview 177
5.123.1 Vanderbilt University Pipeline Products & Ongoing Clinical Trials Overview 177
5.124 Vastcon Inc Company Overview 179
5.124.1 Vastcon Inc Pipeline Products & Ongoing Clinical Trials Overview 179
5.125 Viomics Inc. Company Overview 180
5.125.1 Viomics Inc. Pipeline Products & Ongoing Clinical Trials Overview 180
5.126 VolitionRX Ltd Company Overview 181
5.126.1 VolitionRX Ltd Pipeline Products & Ongoing Clinical Trials Overview 181
5.127 XEPTAGEN SpA Company Overview 187
5.127.1 XEPTAGEN SpA Pipeline Products & Ongoing Clinical Trials Overview 187
6 Colorectal Cancer- Recent Developments 188
6.1 Jun 23, 2020: Vall d'Hebron identifies a prognostic marker in rectal cancer based on the intestinal microbiome 188
6.2 May 04, 2020: StageZero Life Sciences announces enhanced relationship with Phleb-Finders 189
6.3 Apr 29, 2020: Cancer testing and diagnosis suffers sharp downturn, finds Diaceutics 190
6.4 Apr 15, 2020: Indivumed launches global oncology alliance for personalized medicine ("Onco AI-Med") 191
6.5 Apr 03, 2020: StageZero Life Sciences announces publication of abstract at american society of clinical oncology 192
6.6 Apr 03, 2020: NeoGenomics integrates HALO from Indica Labs 192
6.7 Apr 01, 2020: Genetic Technologies announces market update on sales, early test results and launch of consumer initiated testing 193
6.8 Mar 17, 2020: Olympus supports national colorectal cancer awareness month 194
6.9 Mar 12, 2020: Lineage Cell Therapeutics reports fourth quarter and full year 2019 financial results and provides business update 195
6.10 Mar 06, 2020: 2cureX is accelerating the commercialization of IndiTreat by signing two distributor agreements to prepare for launch in second half of 2020 199
6.11 Mar 05, 2020: Biocartis announces new immuno-oncology project with Bristol-Myers Squibb aimed at registration of Idylla MSI test in China 200
6.12 Mar 05, 2020: Biocartis Group: Biocartis announces 2019 results and 2020 outlook 200
6.13 Mar 04, 2020: Immunoscore in the WHO Classification of Digestive System Tumours 207
6.14 Feb 29, 2020: MGI's response to Illumina's complaint 207
6.15 Feb 26, 2020: MDxHealth reports financial year 2019 results and provides outlook for 2020 208
6.16 Feb 26, 2020: bioMerieux – 2019 financial results 210
6.17 Feb 26, 2020: Mayo Clinic reports 'remarkable growth' in 2019 213
6.18 Feb 25, 2020: TCS digitally transforms Qiagen’s global research platform to improve user experience with new digital capabilities 214
6.19 Feb 19, 2020: Biohit Group financial statement release 2019 214
6.20 Feb 11, 2020: Exact Sciences announces fourth-quarter 2019 results 219
6.21 Feb 10, 2020: PRA Health Sciences reports fourth quarter and full year 2019 results and provides first quarter and full year 2020 guidance 220
6.22 Feb 06, 2020: Dr. Scott Gottlieb, former US FDA Commissioner, joins Illumina’s Board of Directors 222
6.23 Feb 06, 2020: Myriad announces leadership transition 222
6.24 Feb 06, 2020: Myriad Genetics reports fiscal second-quarter 2020 financial results 223
6.25 Feb 06, 2020: Dr. Scott Gottlieb, former US FDA Commissioner, joins Illumina’s Board of Directors 225
6.26 Jan 30, 2020: Update on 2cureX’s clinical trial in metastatic colorectal cancer: 75% of the scheduled patients have been treated in accordance with the IndiTreat test 225
6.27 Jan 30, 2020: Theradiag reports 2019 revenue of €9.6 million, Up
8.3% 226
6.28 Jan 30, 2020: OGT launches breakthrough NGS panel for constitutional cytogenetics 228
6.29 Jan 27, 2020: Biocartis announces resignation CFO 229
6.30 Jan 21, 2020: Biomark’s scientific advisor named Dean of the Schulich School of Medicine and Dentistry 229
6.31 Jan 14, 2020: Dr. Thomas P. Slavin named Senior Vice President of Medical Affairs for Myriad Oncology 229
6.32 Jan 12, 2020: Exact Sciences announces preliminary fourth quarter 2019 results 230
6.33 Jan 09, 2020: Biocartis meets 2019 key business objectives 231
6.34 Jan 07, 2020: Jant Pharmacal is awarded contract from Vizient 232
6.35 Jan 02, 2020: Lineage Cell Therapeutics conducts sale of shares in oncocyte 232
6.36 Dec 31, 2019: Biomark announces appointment of Scientific and Medical Advisors, grant of stock options and changes in Board Of Directors 233
6.37 Dec 29, 2019: Illumina reports financial results for fourth quarter and fiscal year 2019 233
6.38 Dec 23, 2019: Mayo Clinic names chief digital officer to lead transformative digital strategy, create Center for Digital Health 235
6.39 Dec 19, 2019: Biomark Diagnostics reviews 2019 and outlines plans for 2020 235
6.40 Dec 18, 2019: A new biomarker for colorectal cancer 239
6.41 Dec 13, 2019: Hospitals and cancer care givers can now offer the IndiTreat test to their cancer patients. 239
6.42 Dec 13, 2019: 2cureX presented progression in the IndiTreat immuno-oncology assay development at the ESMO Immuno-Oncology Congress in Geneva 239
6.43 Dec 13, 2019: NetScientific announces changes to its Board of Directors 240
6.44 Dec 10, 2019: 2cureX launches IndiTreat.com as an important component of 2cureX’s preparation for the product launch of IndiTreat in 2020 241
6.45 Dec 03, 2019: Dr. John Halamka named president of Mayo Clinic Platform 241
6.46 Nov 21, 2019: Development of colorectal cancer detection kit 242
6.47 Nov 21, 2019: Pacific Edge announces FY20 results and capital raising 243
6.48 Nov 19, 2019: Epigenomics reports financial results for the first nine months 2019 246
6.49 Nov 15, 2019: StageZero Life Sciences announces Q3 2019 progress update 247
6.50 Nov 14, 2019: Biocartis Q3 2019 business update 248
6.51 Nov 14, 2019: BioIQ conducts one millionth colorectal cancer screening 251
6.52 Nov 14, 2019: Biocartisb Q3 2019 business update 251
6.53 Nov 12, 2019: Lineage Cell Therapeutics reports third quarter 2019 financial results and provides business update 253
6.54 Nov 12, 2019: VolitionRx announces third quarter 2019 financial results and business update 256
6.55 Nov 12, 2019: Vermillion reports third quarter 2019 financial results 258
6.56 Nov 12, 2019: OGT continues move into molecular diagnostics markets 259
7 Appendix 261
7.1 Methodology 261
7.2 About GlobalData 265
7.3 Contact Us 265
7.4 Disclaimer 265